Clinical Trials Directory

Trials / Completed

CompletedNCT05131061

68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism

68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Qifu Li · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers

Summary

To evaluate the value of 68Ga-Pentixafor PET/CT in the diagnosis of primary aldosteronism subtype

Detailed description

This is a prospective study. We will enroll 100 patients with definite diagnosis of PA using adrenal venous sampling(AVS) as the gold standard for subtype to evaluate the value of 68Ga-pentixaforPET/CT in the diagnosis of PA.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST68Ga-Pentixafor PET/CT imaging68Ga-Pentixafor PET/CT imaging

Timeline

Start date
2021-11-11
Primary completion
2022-05-01
Completion
2022-05-31
First posted
2021-11-23
Last updated
2022-07-15

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05131061. Inclusion in this directory is not an endorsement.